Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
Launched by ASAN MEDICAL CENTER · Jun 21, 2010
Trial Information
Current as of August 02, 2025
Terminated
Keywords
ClinConnect Summary
The investigators are trying to establish that routine clinical practice for voriconazole therapeutic drug monitoring can improve the efficacy and safety outcomes.
In Korean patients with hematologic malignancy, the investigators also want to propose the optimal dosing guideline of voriconazole with different genetic polymorphisms.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: all items below
- • male or female ≥ 15 years of age
- • immunocompromised patients with hematologic disorders
- • patients received voriconazole due to treat proven, probable invasive (pulmonary) aspergillosis
- Exclusion Criteria:
- • severe hepatic dysfunction (t.bil, AST, ALT, ALP \> 5 x upper normal limit)
- • who experienced hypersensitivity to azoles
- • pregnant women
About Asan Medical Center
Asan Medical Center, located in Seoul, South Korea, is a leading healthcare institution renowned for its commitment to advanced medical research and patient care. With a focus on innovative clinical trials, the center aims to enhance healthcare outcomes through rigorous scientific investigation and collaboration. Asan Medical Center is equipped with state-of-the-art facilities and a multidisciplinary team of experts dedicated to exploring new therapeutic approaches across various medical fields. Its robust infrastructure supports a wide range of clinical studies, contributing significantly to the global medical community's understanding of diseases and treatment efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials